Polyphyllin D-loaded solid lipid nanoparticles for breast cancer: Synthesis, characterization, in vitro, and in vivo studies

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

“…In contrast, the in vitro cytotoxicity of triple-negative MDA-MB-231 cell lines revealed a 2.63-fold decrease in IC 50 with a greater antimigratory impact and cellular uptake compared to PTS solution . In addition to their in vivo antitumor activity in an orthotopic cancer model, the CS/Lf/PTS-SLNs reduced tumor growth by 2.4-fold when compared to the PTS solution . Moreover, the results are also summarized in Table .…”

“…PD-loaded SLNs downregulated B-cell lymphoma 2 (Bcl-2) and 70 kDa heat shock proteins (HSP70) while upregulating P-53, apoptotic protease activating factor 1 (Apaf-1), p-53, and Noxa proteins. In vivo studies showed maximum tumor inhibitory action on 4T 1 -implanted BALB/c mice . Therefore, it is concluded that PD-loaded SLNs may become promising in the management of BC without recognizable side effects.…”

“…In certain malignancies, it induces apoptosis . Its applications are limited because it causes hemolysis . Researchers developed and optimized PD-loaded SLNs and used them against BC cell lines.…”

“… 59 In addition to their in vivo antitumor activity in an orthotopic cancer model, the CS/Lf/PTS-SLNs reduced tumor growth by 2.4-fold when compared to the PTS solution. 60 Moreover, the results are also summarized in Table 2 . Furthermore, the immune-histochemistry experiment revealed that CS/Lf/PTS-SLNs had a greater antitumorogenic impact through a 5.87-fold reduction in Bcl-2 expression as compared to PTS solution.…”

“… 58 Its applications are limited because it causes hemolysis. 60 Researchers developed and optimized PD-loaded SLNs and used them against BC cell lines. The IC 50 values were 33.25 and 35.74 μg/mL for MCF-7 and MDA-MB-231 cells, respectively.…”